GSK results: Little room for error on £40bn sales target
Max Stanyard, Healthcare and Life Sciences Senior Analyst at RSM UK, comments on GSK's latest results:
“GSK delivered Q2 revenue growth of 5% driven primarily by Specialty Medicines and Vaccines, while General Medicines continued to act as a drag.
“The context of GSK’s portfolio growth update was a familiar one. GSK has long targeted £40bn in sales by 2031, a figure analysts have persistently priced roughly £4bn short. CEO Miels has today set out his path to closing that gap, revolving around a sharply accelerated late-stage pipeline and oncology as the new growth pillar. This will be funded by a £1.9bn-a-year cost reallocation programme and underpinned by a rebuilt R&D operation moving from Stevenage to a new Cambridge hub.
"That path faces three material headwinds. First, GSK's HIV franchise, its fastest-growing business, faces the sharp edge of the patent cliff when dolutegravir loses exclusivity from 2028, putting over £5.6bn of revenue at risk. Second, the late-stage failure of a potential game-changing drug to treat chronic cough earlier this month has removed one prospective growth driver. So, the remaining bridge depends on pipeline execution across multiple late-stage assets, from lung cancer candidates to the ramp-up of Exdensur's in the US, landing broadly on schedule. On top of that, GSK is carrying its own execution risk: £2.4bn of restructuring costs and a live site closure to fund the plan it just announced.
“This doesn’t mean the £40bn target is unreachable, but it demonstrates that GSK has limited room left to absorb further setbacks. Today's update replaced a strategic gap with a clear execution plan. GSK has now shown its workings, and delivery against this specific, dense timeline becomes the test."